This Funding Opportunity Announcement (FOA) is associated with the Beau Biden Cancer MoonshotSM Initiative that is intended to accelerate cancer research. The purpose of this FOA is to increase case ascertainment and appropriate follow-up care, optimizing the delivery of evidence-based healthcare for individuals at high risk of cancer due to an inherited genetic susceptibility.

Eligibility Requirements: Applicants of non-Japanese nationality; a Doctorate degree; must be 49 years old or under;  not have been in Japan previously; have firm positions and professions in their home nations; etc. Host Institution In Japan: Applicants are free to select host institutions (university research laboratories, national research institutions or the corresponding facilities of private industry) Fellowship Details: Stipend for research and stay, Insurance, Air transportation (a round-trip air ticket to/from Tokyo) and Lump sum on arrival Period & Number of Fellowships: For a period of from three to six months; the number of fellowships is about 20 persons each year.

Through this limited competition Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) solicits a single application for the continuation of the AIDS and Cancer Specimen Resource (ACSR). The eligible applicant institutions (which are the two current NCI-supported ACSR lead institutions) are expected to maintain the cooperative group structure and the activities of the ACSR. The primary objective of the ACSR will be to acquire, store, and equitably distribute tumor tissues, biological fluids, and associated demographic data from patients with human immunodeficiency virus (HIV)-associated malignancies. In addition to serving acquired immunodeficiency syndrome (AIDS) and cancer researchers at large, the ACSR will specifically provide biorepository functions for another NCI supported initiative, the AIDS Malignancy Consortium (AMC). The AMC performs clinical trials research in the treatment and prevention of HIV-associated malignancies in the United States and Sub-Saharan Africa. As the AMC is currently expanding its agenda to include Latin America, it is expected that the ACSR will collaborate with the AMC to develop regional biorepository support for AMC activities in Latin American countries. The continuing ACSR must have appropriate strategies and capabilities to address several high priority areas of specimen acquisition including specific types of cancer (AIDS-defining as well as non-AIDS defining), types of biospecimens and accompanying clinical data, and biospecimens from geographic areas of interest.

This Funding Opportunity Announcement (FOA) invites grant applications for the Research Specialist Award (R50) in any area of NCI-funded cancer research. This FOA is specifically for core/shared resource/central scientific support scientists. The Research Specialist Award is designed to encourage the development of stable research career opportunities for exceptional scientists who want to continue to pursue research within the context of an existing NCI-funded basic, translational, clinical or population science cancer research program, but not serve as independent investigators. These scientists, such as researchers within a core/shared resource/central scientific support, are vital to sustaining the biomedical research enterprise. The Research Specialist Award is intended to provide salary support and sufficient autonomy so that individuals are not solely dependent on NCI grants held by others for career continuity.

This Funding Opportunity Announcement (FOA) invites grant applications for the Research Specialist Award (R50) in any area of NCI-funded cancer research. This FOA is specifically for core/shared resource/central scientific support scientists. The Research Specialist Award is designed to encourage the development of stable research career opportunities for exceptional scientists who want to continue to pursue research within the context of an existing NCI-funded basic, translational, clinical or population science cancer research program, but not serve as independent investigators. These scientists, such as researchers within a core/shared resource/central scientific support, are vital to sustaining the biomedical research enterprise. The Research Specialist Award is intended to provide salary support and sufficient autonomy so that individuals are not solely dependent on NCI grants held by others for career continuity.

The intent of the GWIRP NIA is to support investigators new to the field of GWI research at different stages of career development. This award enables such investigators to compete for funding separately from investigators with established programs of GWI research. Previous experience in GWI research is allowed, but not required. However, applications naming a Principal Investigator (PI) with limited background in GWI research are strongly encouraged to include collaboration with investigators who are experienced in GWI research and/or possess other relevant expertise to strengthen the application. The application should describe how the collaboration(s) will augment the PI's ability to address the research question.

This Funding Opportunity Announcement (FOA) invites grant applications for the Outstanding Investigator Award (R35) in any area of cancer research. The objective of the National Cancer Institute (NCI) Outstanding Investigator Award (OIA) is to provide long-term support to accomplished investigators with outstanding records of cancer research productivity who propose to conduct exceptional research. The OIA is intended to allow investigators the opportunity to take greater risks, be more adventurous in their lines of inquiry, or take the time to develop new techniques. The OIA would allow an Institution to submit applications nominating established Program Directors/Principal Investigators (PDs/PIs) for the NCI OIA. It is expected that the OIA would provide extended funding stability and encourage investigators to embark on projects of unusual potential in cancer research. The research projects should break new ground or extend previous discoveries toward new directions or applications that may lead to a breakthrough that will advance biomedical, behavioral, or clinical cancer research.

This funding opportunity announcement (FOA) invites applications for research in cancer control and population sciences. The overarching goal is to provide support to promote research efforts on novel scientific ideas that have the potential to substantially advance cancer research in statistical and analytic methods, epidemiology, cancer survivorship, cancer-related behaviors and behavioral interventions, health care delivery, and implementation science.

Through the program, the center will award grants of up to $120,000 over two years to promising laboratory and clinical scientists pursuing careers as independent investigators in ovarian cancer research. Funds are for direct costs only; institutional overhead and indirect costs will not be included in the award.

Impact: Research supported by the Breakthrough Award will have the potential for a major impact and accelerate progress toward ending breast cancer. The impact may be near-term or long-term, but must move beyond a minor advancement and have the potential to lead to a new approach that is fundamentally better than interventions already approved or in clinical development. Applications are expected to identify the breast cancer patients or at-risk individuals who would ultimately benefit from the proposed research.

Impact: Research supported by the Breakthrough Award will have the potential for a major impact and accelerate progress toward ending breast cancer. The impact may be near-term or long-term, but must move beyond a minor advancement and have the potential to lead to a new approach that is fundamentally better than interventions already approved or in clinical development. Applications are expected to identify the breast cancer patients or at-risk individuals who would ultimately benefit from the proposed research.

The Conquer Cancer Foundation was created by the American Society of Clinical Oncology to drive dramatic advances in the prevention, treatment, and cures of all types of cancer. CCF works to conquer cancer by funding breakthrough cancer research and sharing cutting-edge knowledge with patients and physicians worldwide, improving quality of and access to care, and enhancing quality of life for all who are touched by cancer.

The annual program provides start-up funding to basic scientists and clinicians in a position to test innovative ideas for improving the diagnosis of and new treatment modalities for pancreatic cancer; obtain preliminary data required for additional funding from other agencies for pancreatic cancer research;  advance the understanding of pancreatic cancer cell biology, biochemistry, physiology, morphology and response to therapy; and establish collaborations within the field that can be considered for further funding. The foundation expects that seed grant awards will generate quality abstracts, papers, and presentations, as well as new proposals. Priority will be given to investigators whose primary intent is to build a strong curriculum in pancreatic cancer research.

The FY18 PRCRP Horizon Award supports junior-level scientists in conducting impactful research with the mentorship of an experienced cancer researcher (i.e., Mentor). The Horizon Award challenges junior scientists to develop and implement research in the cancer field. This opportunity allows for junior investigators to develop a research project, investigate a problem or question in the field of cancer, and further their intellectual development as a cancer researcher of the future.

The annual prize, named in honor of Albert Szent-Györgyi, Nobel Laureate and co-founder of NFCR, is awarded to an outstanding researcher whose scientific achievements have expanded our understanding of cancer and whose discoveries have made possible new approaches to the prevention, diagnosis, and/or treatment of cancer.

The purpose of this Funding Opportunity Announcement (FOA) is to incentivize collaborative, multidisciplinary research across a broad area of challenging topics in basic cancer biology. These supplement applications must propose a collaboration between at least two researchers, one being the PI of the parent NCI grant. Awarded supplements will leverage and extend currently funded cancer research in the parent grant.

The purpose of this Funding Opportunity Announcement (FOA) is to invite Cooperative Agreement applications to develop research resources that will encourage a consensus on how Quantitative Imaging (QI) methods are optimized to improve the quality of imaging results for co-clinical trials. The scientific goals of this FOA are to: (a) perform the appropriate optimization of the pre-clinical quantitative imaging methods, (b) implement the optimized methods in the co-clinical trial, and finally (c) populate a web-accessible research resource with all the data, methods, workflow documentation, and results collected from the co-clinical investigations. Co-clinical trials are defined in this FOA as investigations in patients and in parallel (or sequentially) in mouse or human-in-mouse models of cancer that mirror the genetics and biology of the patients malignancies or pre-cancerous lesions. The co-clinical trial should include either (a) a therapeutic goal, such as the prediction, staging, and/or measurement of tumor response to therapies, or (b) a screening and early detection or a cancer risk stratification goal for lethal cancer versus non-lethal disease. Applicants are encouraged to organize multi-disciplinary teams with experience in mouse models research, human investigations, imaging platforms, QI methods, decision support software and informatics to populate the research resource.

The purpose of this trans-NCI Funding Opportunity Announcement (FOA) is to promote new cancer disparities research among investigators who do not normally conduct it and to encourage the partnership of experienced cancer research investigators with cancer disparities-focused researchers. This FOA is intended to accelerate and strengthen multi-disciplinary cancer disparities research in wide-ranging areas. Cancer disparities research includes, but is not limited to basic, translational, behavioral, observational, interventional, environmental and population research studies that address the adverse differences in cancer incidence, prevalence, mortality, survivorship, burden and/or response to treatment in racial/ethnic minorities and/or underserved population groups. Proposed collaborations should focus on achieving research objectives that by necessity rely on diverse and complementary expertise, technical capabilities, and resource sets. Importantly, the supplemental proposal is required to be within the scope of the parent award and should expand the original aims to include a cancer disparity component.

The purpose of this trans-NCI Funding Opportunity Announcement (FOA) is to promote new cancer disparities research among investigators who do not normally conduct it and to encourage the partnership of experienced cancer research investigators with cancer disparities-focused researchers. This FOA is intended to accelerate and strengthen multi-disciplinary cancer disparities research in wide ranging areas. Cancer disparities research includes, but is not limited to basic, translational, behavioral, observational, interventional, environmental and population research studies that address the adverse differences in cancer incidence, prevalence, mortality, survivorship, burden and/or response to treatment in racial/ethnic minorities and/or underserved population groups. Proposed collaborations should focus on achieving research objectives that by necessity rely on diverse and complementary expertise, technical capabilities, and resource sets. Importantly, the supplemental request is required to be within the scope of the parent award and should expand the original aims to include a cancer disparity component.

The purpose of this Funding Opportunity Announcement (FOA) is to invite Cooperative Agreement applications to develop research resources that will encourage a consensus on how Quantitative Imaging (QI) methods are optimized to improve the quality of imaging results for co-clinical trials. The scientific goals of this FOA are to: (a) perform the appropriate optimization of the pre-clinical quantitative imaging methods, (b) implement the optimized methods in the co-clinical trial, and finally (c) populate a web-accessible research resource with all the data, methods, workflow documentation, and results collected from the co-clinical investigation